| Literature DB >> 27390650 |
Estelle Guerdoux-Ninot1, Robert D Kilgour2, Chloé Janiszewski3, Marta Jarlier4, Jocelyne Meuric5, Brigitte Poirée6, Solange Buzzo7, Grégory Ninot1, Julie Courraud8, Wendy Wismer9, Simon Thezenas4, Pierre Senesse10.
Abstract
PURPOSE: The present study examined patient self-reports of descriptions, experiences and consequences of meal disturbances and food preferences within a cultural context (i.e., French meal traditions) in various treated cancer patients along their disease trajectory.Entities:
Keywords: Cancer; Feeding behaviors; Food preferences; Meal context; Taste; Weight loss
Year: 2016 PMID: 27390650 PMCID: PMC4916076 DOI: 10.1186/s40064-016-2538-1
Source DB: PubMed Journal: Springerplus ISSN: 2193-1801
Self-report questionnairea
| #1 Cancer treatment side effects and their impact on eating and drinking | |
| #1.1 | Describe the side effects induced by the treatment: nausea, swallowing difficulties, mouth ulcers, constipation, dry mouth, chewing difficulties, persistent taste, diarrhea, fatigue, hypersensitivity to odors, vomiting, and/or others. |
| #1.2 | Do these side effects disturb your eating and drinking? Yes or no. |
| If yes, describe how: appetite loss, mouth and esophagus pain, fast fullness, food aversion, digestion pain, and/or other. | |
| #1.3 | How long do these difficulties persist after treatment? |
| #2 Cooking skills | |
| #2.1 | Are you able to cook as soon as you come back home? Yes, no or only after |
| #2.2 | Are you helped by: a parent/family member/relative, home delivery, ready-to-eat products, and/or others? |
| #3 Dietary behavior | |
| #3.1 | What meals and/or snacks do you currently have in one day? Breakfast, light morning meal, lunch, light mid-afternoon meal, dinner, and/or other. |
| #3.2 | What is currently your favorite meal? Breakfast, light morning meal, lunch, light mid-afternoon meal, dinner, and/or no preference. |
| #3.3 | What portion would you eat if a full meal was served to you in the hospital or at home? For the first course, for the second course, for the cheese and/or yogurt, for the dessert, and/or for the snack, would you eat 0, 1/4, 1/2, 3/4, 1 or 2 portions? |
| #4 Food preferences | |
| #4.1 | What do you currently prefer to eat: salty, sweet, hot, cold, into pieces, minced, blended, creamy, liquid, and/or other? |
| #4.2 | Since the beginning of the treatment, what food, salty or sweet courses do you prefer to eat? |
| #4.3 | Specify for what foods you have developed nausea or an aversion. |
| #4.4 | What are the most important food attributes that stimulate your appetite (in descending order of importance from 1 to 7): taste, aspect, odor, consistency, quantity, presentation, and/or other? |
| #4.5 | What type of snacks do you prefer to eat: salty, sweet, creamy desserts, ice creams, biscuits, milky beverages, others beverages, and/or others? |
| #5 Nutrient-enriched foods | |
| #5.1 | Have you already experimented with enriched or fortified foods? Yes or no. |
| If yes, in what context have you experimented with it: in the hospital, at home, and/or, other? | |
| If yes, please specify: blended courses, creamy desserts, milky beverages, non-milky beverages, and/or others? | |
| If yes, are you satisfied with the products: very satisfied, satisfied or not satisfied? Please specify why. | |
| #6 Preferences for a new dietary product | |
| #6.1 | If new dietary products were developed, what advantages would motivate you to purchase them (in descending order of importance from 1 to 9): taste, sale price, ready-to-eat, dietary counseling, medical prescription, mode of preservation, nutritional value, partial reimbursement, or others? |
| #6.2 | Where do you prefer to find these new products: pharmacies, dietary shops, supermarkets, and/or home delivery? |
| #6.3 | What type of new products would you prefer: frozen, canned, fresh or other? |
aTranslated from French to English
Patient demographic and clinical characteristics (n = 255)
| Characteristic |
|
|---|---|
| Age | |
| <60 years | 111 (43.5) |
| ≥60 years | 144 (56.5) |
| Female sex | 153 (60.0) |
| ECOG performance statusa | |
| 0 | 76 (29.8) |
| 1 | 100 (39.2) |
| 2 | 72 (28.2) |
| Side effects on oral intake | 244 (95.7) |
|
| |
| (0–6) | 90 (35.3) |
| (7 and 8) | 48 (18.8) |
| (8–10) | 100 (39.2) |
| Artificial nutrition | 38 (15.8) |
| Personal and professional status | |
| Live in southern France | 143 (56.1) |
| As a couple | 178 (69.8) |
| Activec | 27 (10.6) |
| Inactived | 123 (48.2) |
| Sick leave | 77 (30.2) |
| Tumor location | |
| Breast | 69 (27.1) |
| Digestive system | 56 (22.0) |
| Head and neck | 33 (12.9) |
| Hematopoietic system | 18 (7.1) |
| Lung | 17 (6.7) |
| Gynecology | 17 (6.7) |
| Others | 35 (13.7) |
| Anticancer treatment | |
| Chemotherapy | 182 (71.4) |
| Radiotherapy | 7 (2.7) |
| Chemotherapy + radiotherapy | 26 (10.2) |
| Surgery | 23 (9.0) |
| Others (e.g., antibiotic therapy) | 11 (4.3) |
| Weight loss (compared with baseline) (%) | |
| <5 | 121 (47.5) |
| 5–10 | 59 (23.1) |
| 10–20 | 53 (20.8) |
| ≥20 | 13 (5.1) |
aThe Eastern Cooperative Oncology Group (ECOG) performance status refers to functional ability scores (ranged from 0 to 5) to quantify cancer patients general well-being and activities of daily life
bThe ingesta visual/verbal analogue scale is used for a quick assessment of dietary intake in clinical practice, particularly in patients with weight loss (0 = no ingesta; 10 = usual ingesta). This scale is highly correlated with caloric intake. Patients defined themselves their level of ingestion of food between 0 (nothing) and 10 (as usual)
cPatients were considered to be active if they had a job
dPatients were considered to be inactive if they had no job or were retired
Treatment side effects
| Type of side effects ( |
|
|---|---|
| Fatigue | 190 (74.5) |
| Nausea | 141 (55.3) |
| Dry mouth | 124 (48.6) |
| Hypersensitivity to odors | 91 (35.7) |
| Constipation | 87 (34.1) |
| Diarrhea | 83 (32.5) |
| Mouth ulcers | 64 (25.1) |
| Swallowing difficulties | 62 (24.3) |
| Vomiting | 55 (21.6) |
| Persistent taste | 36 (14.1) |
| Chewing difficulties | 35 (13.7) |
| Others (e.g., dysgeusia) | 52 (20.4) |
Side effects and oral intake impact
| Type of perturbation of oral intake ( |
|
|---|---|
| Appetite loss | 143 (66.8) |
| Food aversion | 110 (51.4) |
| Satiety | 85 (39.7) |
| Mouth pain | 54 (25.2) |
| Abdominal pain during digestion | 26 (12.1) |
| Others (e.g., ageusia) | 23 (10.7) |
Food preferences and aversions in cancer patients
|
| |
|---|---|
| Main preferences ( | |
| Fruits | 100 (48.8) |
| Dairy products | 92 (44.9) |
| Pasta | 86 (42.0) |
| Red meat | 82 (40.0) |
| Mashed potatoes | 74 (36.1) |
| Vegetables | 74 (36.1) |
| Soup | 68 (33.2) |
| Fish | 62 (30.2) |
| White meat | 42 (20.5) |
| Milky dessert | 40 (19.5) |
| Rice | 26 (12.7) |
| Salad | 20 (9.8) |
| Main food aversions ( | |
| Red meat | 27 (15.4) |
| Meals and meat with sauce | 19 (10.9) |
| Everything | 13 (7.4) |
| Sweet | 9 (5.1) |
| Chocolate | 7 (4.0) |
| Cheese | 7 (4.0) |
| Coffee | 7 (4.0) |
Fig. 1Percentage of patients who chose a characteristic (among taste, appearance, odor, consistency, quantity, packaging and other) as the most important sensory quality that stimulates appetite (n = 255)